Orphazyme A/S
Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. The company was founded in 2009 and is based in Herlev, Denmark.
Orphazyme A/S (OZYMF) - Total Assets
Latest total assets as of June 2025: $18.85 Million USD
Based on the latest financial reports, Orphazyme A/S (OZYMF) holds total assets worth $18.85 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Orphazyme A/S - Total Assets Trend (2013–2024)
This chart illustrates how Orphazyme A/S’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Orphazyme A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
Orphazyme A/S's total assets of $18.85 Million consist of 84.9% current assets and 15.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Orphazyme A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orphazyme A/S's current assets represent 84.9% of total assets in 2024, a decrease from 94.7% in 2013.
- Cash Position: Cash and equivalents constituted 16.5% of total assets in 2024, down from 72.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Orphazyme A/S Competitors by Total Assets
Key competitors of Orphazyme A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Orphazyme A/S - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Orphazyme A/S generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Orphazyme A/S is currently not profitable relative to its asset base.
Orphazyme A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.36 | 10.14 | 5.24 |
| Quick Ratio | 19.36 | 10.14 | 5.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.49 Million | $ 16.09 Million | $ 516.38 Million |
Orphazyme A/S - Advanced Valuation Insights
This section examines the relationship between Orphazyme A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.28 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 22.0% |
| Total Assets | $23.56 Million |
| Market Capitalization | $1.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Orphazyme A/S's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Orphazyme A/S's assets grew by 22.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Orphazyme A/S (2013–2024)
The table below shows the annual total assets of Orphazyme A/S from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $23.56 Million | +21.99% |
| 2023-12-31 | $19.31 Million | -66.02% |
| 2022-12-31 | $56.83 Million | -67.20% |
| 2021-12-31 | $173.23 Million | -78.94% |
| 2020-12-31 | $822.49 Million | +355.03% |
| 2019-12-31 | $180.75 Million | -59.05% |
| 2018-12-31 | $441.35 Million | -33.41% |
| 2017-12-31 | $662.82 Million | +1975.13% |
| 2016-12-31 | $31.94 Million | -62.40% |
| 2015-12-31 | $84.95 Million | -10.90% |
| 2014-12-31 | $95.35 Million | +168.10% |
| 2013-12-31 | $35.56 Million | -- |